ATE394102T1 - Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren - Google Patents

Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren

Info

Publication number
ATE394102T1
ATE394102T1 AT01944061T AT01944061T ATE394102T1 AT E394102 T1 ATE394102 T1 AT E394102T1 AT 01944061 T AT01944061 T AT 01944061T AT 01944061 T AT01944061 T AT 01944061T AT E394102 T1 ATE394102 T1 AT E394102T1
Authority
AT
Austria
Prior art keywords
aurora
kinase inhibitors
quinazoline derivatives
substituted quinazoline
substituted
Prior art date
Application number
AT01944061T
Other languages
English (en)
Inventor
Andrew Mortlock
Frederic Jung
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE394102T1 publication Critical patent/ATE394102T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01944061T 2000-06-28 2001-06-21 Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren ATE394102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00401842 2000-06-28

Publications (1)

Publication Number Publication Date
ATE394102T1 true ATE394102T1 (de) 2008-05-15

Family

ID=8173742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01944061T ATE394102T1 (de) 2000-06-28 2001-06-21 Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren

Country Status (26)

Country Link
US (2) US6919338B2 (de)
EP (1) EP1299381B1 (de)
JP (1) JP2004501914A (de)
KR (1) KR20030014411A (de)
CN (1) CN1267431C (de)
AR (1) AR030432A1 (de)
AT (1) ATE394102T1 (de)
AU (1) AU2001266505A1 (de)
BG (1) BG107376A (de)
BR (1) BR0111754A (de)
CA (1) CA2412592A1 (de)
CZ (1) CZ20024120A3 (de)
DE (1) DE60133897D1 (de)
EE (1) EE200200715A (de)
ES (1) ES2305081T3 (de)
HU (1) HUP0301236A2 (de)
IL (1) IL153246A0 (de)
IS (1) IS6656A (de)
MX (1) MXPA02011974A (de)
NO (1) NO20026010D0 (de)
NZ (1) NZ522696A (de)
PL (1) PL360439A1 (de)
RU (1) RU2283311C2 (de)
SK (1) SK18102002A3 (de)
WO (1) WO2002000649A1 (de)
ZA (1) ZA200209412B (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (de) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als protein-kinasehemmer
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
DE60234125D1 (de) * 2001-12-24 2009-12-03 Astrazeneca Ab E inhibitoren
EP1472245A2 (de) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl-verbindungen und ihre anwendung als gsk-3-hemmer
JP4481011B2 (ja) 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
EP1501829B1 (de) * 2002-05-06 2010-11-24 Vertex Pharmaceuticals Incorporated Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP2280003B1 (de) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
DK1532145T3 (da) 2002-08-02 2007-01-15 Vertex Pharma Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
ES2290529T3 (es) * 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
MXPA05006920A (es) 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
UA86470C2 (ru) * 2002-12-24 2009-04-27 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
CN1809557B (zh) 2003-04-16 2012-07-04 阿斯利康(瑞典)有限公司 化合物
EP1635823A1 (de) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonisten in der behandlung amyloidosis und anderer assoziierten krankheiten
ATE401080T1 (de) * 2003-06-02 2008-08-15 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
AU2004282179B2 (en) * 2003-10-14 2011-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CN1890223A (zh) * 2003-10-31 2007-01-03 神经能质公司 辣椒素受体促效剂
AU2004297235A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
WO2005066152A1 (en) * 2003-12-30 2005-07-21 The Brigham And Women's Hospital, Inc. Thiophene derivatives for up-regulating hla-dm activity
EP1734040A4 (de) * 2004-03-23 2007-11-28 Banyu Pharma Co Ltd Substituiertes chinazolin- oder pyridopyrimidinderivat
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1778669A2 (de) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
EP1802591B1 (de) * 2004-10-12 2012-01-11 AstraZeneca AB Chinazolinderivate
EP1802603A1 (de) * 2004-10-12 2007-07-04 AstraZeneca AB Chinolinderivate
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
AU2006279376B2 (en) * 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1954277B1 (de) * 2005-11-03 2017-01-18 Vertex Pharmaceuticals Incorporated Als kinaseinhibitoren geeignete aminopyrimidine
EP1785420A1 (de) * 2005-11-14 2007-05-16 4Sc Ag Thiazolanalogen und ihre Verwendung
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20090076075A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
WO2008055233A1 (en) * 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
MX2009004807A (es) * 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
NZ577768A (en) * 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
MX2009009592A (es) * 2007-03-09 2009-11-10 Vertex Pharma Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009009590A (es) * 2007-03-09 2009-11-10 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
ATE526328T1 (de) * 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
AU2008247592A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CN101679387A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
JP5389786B2 (ja) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
MX2009012719A (es) * 2007-05-24 2010-02-04 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
ES2395581T3 (es) * 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
WO2008157575A1 (en) * 2007-06-21 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101790532B (zh) * 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
ES2413806T3 (es) * 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP4585589A3 (de) * 2008-12-03 2025-11-19 The Scripps Research Institute Stammzellenkulturen
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
NZ595087A (en) * 2009-02-11 2013-03-28 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
CN103788085B (zh) * 2012-10-31 2016-09-07 复旦大学 2-（喹唑啉-4-氨基）-5-噻唑甲酰胺类衍生物及其生物药物用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
ES2640648T3 (es) 2013-09-16 2017-11-03 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
US20220289692A1 (en) * 2019-09-06 2022-09-15 Inflazome Limited Nlrp3 inhibitors
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP3901151B1 (de) * 2020-04-21 2026-04-01 iOmx Therapeutics AG Halogenierte heteroaryl- und andere heterocyclische kinaseinhibitoren und verwendungen davon
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种氨基噻唑类化合物的合成方法
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
EP4346806A4 (de) * 2021-05-25 2025-07-23 Biocryst Pharm Inc Imidazolhaltige alk2-kinasehemmer
CN115557601B (zh) * 2022-11-08 2024-11-08 成都理工大学 生物质微球及其制备方法与应用、生物反应器、地下井
AU2024231943A1 (en) * 2023-03-09 2025-10-16 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
US5651028A (en) * 1995-05-09 1997-07-22 Unisys Corporation Data transmission system with a low peak-to-average power ratio based on distorting frequently occuring signals
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR100860295B1 (ko) * 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2004501914A (ja) 2004-01-22
EP1299381B1 (de) 2008-05-07
IS6656A (is) 2002-12-17
IL153246A0 (en) 2003-07-06
BG107376A (bg) 2003-09-30
RU2283311C2 (ru) 2006-09-10
NZ522696A (en) 2004-08-27
MXPA02011974A (es) 2004-09-06
ZA200209412B (en) 2004-02-19
EP1299381A1 (de) 2003-04-09
US6919338B2 (en) 2005-07-19
CA2412592A1 (en) 2002-01-03
PL360439A1 (en) 2004-09-06
WO2002000649A9 (en) 2007-09-20
US20060046987A1 (en) 2006-03-02
HUP0301236A2 (hu) 2003-10-28
KR20030014411A (ko) 2003-02-17
CN1267431C (zh) 2006-08-02
CN1496364A (zh) 2004-05-12
AR030432A1 (es) 2003-08-20
AU2001266505A1 (en) 2002-01-08
EE200200715A (et) 2004-08-16
WO2002000649A1 (en) 2002-01-03
NO20026010L (no) 2002-12-13
BR0111754A (pt) 2003-04-29
CZ20024120A3 (cs) 2003-03-12
ES2305081T3 (es) 2008-11-01
US20030187002A1 (en) 2003-10-02
HK1053124A1 (en) 2003-10-10
SK18102002A3 (sk) 2003-07-01
DE60133897D1 (de) 2008-06-19
NO20026010D0 (no) 2002-12-13

Similar Documents

Publication Publication Date Title
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE367381T1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
ATE461171T1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE309224T1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
DE60332023D1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE59908600D1 (de) Substituierte benzimidazole und ihre verwendung als parp inhibitoren
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
ATE268761T1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
DE60104776D1 (de) Diphenylharnstoffderivate und deren Verwendung als alpha2/5-HT2c Antagonisten
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
DE50115716D1 (de) Tetrakisfluoroalkylborat-Salze und deren Verwendung als Leitsalze
DE60107603D1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
ATE340784T1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties